Headlines about Quest Diagnostics (NYSE:DGX) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quest Diagnostics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 47.951283087546 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

NYSE DGX opened at $108.42 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.05 and a current ratio of 1.12. Quest Diagnostics has a 52-week low of $90.10 and a 52-week high of $116.49. The company has a market cap of $14.83 billion, a PE ratio of 20.08, a price-to-earnings-growth ratio of 2.15 and a beta of 0.73.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.76 by ($0.01). Quest Diagnostics had a net margin of 10.56% and a return on equity of 15.45%. The business had revenue of $1.92 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter in the prior year, the business posted $1.55 earnings per share. Quest Diagnostics’s revenue for the quarter was up 3.0% on a year-over-year basis. equities analysts predict that Quest Diagnostics will post 6.59 earnings per share for the current year.

A number of equities analysts have recently commented on DGX shares. Mizuho reaffirmed a “buy” rating on shares of Quest Diagnostics in a research report on Friday, May 25th. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research report on Tuesday, May 22nd. MED lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. Deutsche Bank lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a research report on Wednesday, June 27th. Finally, Barclays reiterated a “hold” rating and set a $120.00 price objective on shares of Quest Diagnostics in a research note on Monday, May 28th. Thirteen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $110.00.

In other Quest Diagnostics news, insider Mark Guinan sold 61,533 shares of the firm’s stock in a transaction that occurred on Friday, May 25th. The shares were sold at an average price of $105.71, for a total value of $6,504,653.43. Following the completion of the sale, the insider now directly owns 119,733 shares in the company, valued at $12,656,975.43. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Stephen H. Rusckowski sold 168,490 shares of the firm’s stock in a transaction that occurred on Friday, May 25th. The shares were sold at an average price of $107.00, for a total transaction of $18,028,430.00. Following the completion of the sale, the chairman now owns 359,559 shares of the company’s stock, valued at $38,472,813. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 340,064 shares of company stock valued at $36,688,570. 1.79% of the stock is owned by insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.